Cargando…

Prevalence of Novel Myositis Autoantibodies in a Large Cohort of Patients with Interstitial Lung Disease

Connective tissue diseases (CTDs) are an important secondary cause of interstitial lung disease (ILD). If a CTD is suspected, clinicians are recommended to perform autoantibody testing, including for myositis autoantibodies. In this study, the prevalence and clinical associations of novel myositis a...

Descripción completa

Detalles Bibliográficos
Autores principales: Moll, Sofia A., Platenburg, Mark G. J. P., Platteel, Anouk C. M., Vorselaars, Adriane D. M., Janssen Bonàs, Montse, Roodenburg-Benschop, Claudia, Meek, Bob, van Moorsel, Coline H. M., Grutters, Jan C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7563342/
https://www.ncbi.nlm.nih.gov/pubmed/32933078
http://dx.doi.org/10.3390/jcm9092944
_version_ 1783595468884803584
author Moll, Sofia A.
Platenburg, Mark G. J. P.
Platteel, Anouk C. M.
Vorselaars, Adriane D. M.
Janssen Bonàs, Montse
Roodenburg-Benschop, Claudia
Meek, Bob
van Moorsel, Coline H. M.
Grutters, Jan C.
author_facet Moll, Sofia A.
Platenburg, Mark G. J. P.
Platteel, Anouk C. M.
Vorselaars, Adriane D. M.
Janssen Bonàs, Montse
Roodenburg-Benschop, Claudia
Meek, Bob
van Moorsel, Coline H. M.
Grutters, Jan C.
author_sort Moll, Sofia A.
collection PubMed
description Connective tissue diseases (CTDs) are an important secondary cause of interstitial lung disease (ILD). If a CTD is suspected, clinicians are recommended to perform autoantibody testing, including for myositis autoantibodies. In this study, the prevalence and clinical associations of novel myositis autoantibodies in ILD are presented. A total of 1194 patients with ILD and 116 healthy subjects were tested for antibodies specific for Ks, Ha, Zoα, and cN1A with a line-blot assay on serum available at the time of diagnosis. Autoantibodies were demonstrated in 63 (5.3%) patients and one (0.9%) healthy control (p = 0.035). Autoantibodies were found more frequently in females (p = 0.042) and patients without a histological and/or radiological usual interstitial pneumonia (UIP; p = 0.010) and a trend towards CTD-ILDs (8.4%) was seen compared with other ILDs (4.9%; p = 0.090). The prevalence of antibodies specific for Ks, Ha, Zoα, and cN1A was, respectively, 1.3%, 2.0%, 1.4%, and 0.9% in ILD. Anti-Ha and Anti-Ks were observed in males with unclassifiable idiopathic interstitial pneumonia (unclassifiable IIP), hypersensitivity pneumonitis (HP), and various CTD-ILDs, whereas anti-cN1A was seen in females with antisynthetase syndrome (ASS), HP, and idiopathic pulmonary fibrosis (IPF). Anti-Zoα was associated with CTD-ILD (OR 2.5; 95%CI 1.11–5.61; p = 0.027). In conclusion, a relatively high prevalence of previously unknown myositis autoantibodies was found in a large cohort of various ILDs. Our results contribute to the awareness that circulating autoantibodies can be found in ILDs with or without established CTD. Whether these antibodies have to be added to the standard set of autoantibodies analysed in conventional myositis blot assays for diagnostic purposes in clinical ILD care requires further study.
format Online
Article
Text
id pubmed-7563342
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-75633422020-10-27 Prevalence of Novel Myositis Autoantibodies in a Large Cohort of Patients with Interstitial Lung Disease Moll, Sofia A. Platenburg, Mark G. J. P. Platteel, Anouk C. M. Vorselaars, Adriane D. M. Janssen Bonàs, Montse Roodenburg-Benschop, Claudia Meek, Bob van Moorsel, Coline H. M. Grutters, Jan C. J Clin Med Article Connective tissue diseases (CTDs) are an important secondary cause of interstitial lung disease (ILD). If a CTD is suspected, clinicians are recommended to perform autoantibody testing, including for myositis autoantibodies. In this study, the prevalence and clinical associations of novel myositis autoantibodies in ILD are presented. A total of 1194 patients with ILD and 116 healthy subjects were tested for antibodies specific for Ks, Ha, Zoα, and cN1A with a line-blot assay on serum available at the time of diagnosis. Autoantibodies were demonstrated in 63 (5.3%) patients and one (0.9%) healthy control (p = 0.035). Autoantibodies were found more frequently in females (p = 0.042) and patients without a histological and/or radiological usual interstitial pneumonia (UIP; p = 0.010) and a trend towards CTD-ILDs (8.4%) was seen compared with other ILDs (4.9%; p = 0.090). The prevalence of antibodies specific for Ks, Ha, Zoα, and cN1A was, respectively, 1.3%, 2.0%, 1.4%, and 0.9% in ILD. Anti-Ha and Anti-Ks were observed in males with unclassifiable idiopathic interstitial pneumonia (unclassifiable IIP), hypersensitivity pneumonitis (HP), and various CTD-ILDs, whereas anti-cN1A was seen in females with antisynthetase syndrome (ASS), HP, and idiopathic pulmonary fibrosis (IPF). Anti-Zoα was associated with CTD-ILD (OR 2.5; 95%CI 1.11–5.61; p = 0.027). In conclusion, a relatively high prevalence of previously unknown myositis autoantibodies was found in a large cohort of various ILDs. Our results contribute to the awareness that circulating autoantibodies can be found in ILDs with or without established CTD. Whether these antibodies have to be added to the standard set of autoantibodies analysed in conventional myositis blot assays for diagnostic purposes in clinical ILD care requires further study. MDPI 2020-09-11 /pmc/articles/PMC7563342/ /pubmed/32933078 http://dx.doi.org/10.3390/jcm9092944 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Moll, Sofia A.
Platenburg, Mark G. J. P.
Platteel, Anouk C. M.
Vorselaars, Adriane D. M.
Janssen Bonàs, Montse
Roodenburg-Benschop, Claudia
Meek, Bob
van Moorsel, Coline H. M.
Grutters, Jan C.
Prevalence of Novel Myositis Autoantibodies in a Large Cohort of Patients with Interstitial Lung Disease
title Prevalence of Novel Myositis Autoantibodies in a Large Cohort of Patients with Interstitial Lung Disease
title_full Prevalence of Novel Myositis Autoantibodies in a Large Cohort of Patients with Interstitial Lung Disease
title_fullStr Prevalence of Novel Myositis Autoantibodies in a Large Cohort of Patients with Interstitial Lung Disease
title_full_unstemmed Prevalence of Novel Myositis Autoantibodies in a Large Cohort of Patients with Interstitial Lung Disease
title_short Prevalence of Novel Myositis Autoantibodies in a Large Cohort of Patients with Interstitial Lung Disease
title_sort prevalence of novel myositis autoantibodies in a large cohort of patients with interstitial lung disease
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7563342/
https://www.ncbi.nlm.nih.gov/pubmed/32933078
http://dx.doi.org/10.3390/jcm9092944
work_keys_str_mv AT mollsofiaa prevalenceofnovelmyositisautoantibodiesinalargecohortofpatientswithinterstitiallungdisease
AT platenburgmarkgjp prevalenceofnovelmyositisautoantibodiesinalargecohortofpatientswithinterstitiallungdisease
AT platteelanoukcm prevalenceofnovelmyositisautoantibodiesinalargecohortofpatientswithinterstitiallungdisease
AT vorselaarsadrianedm prevalenceofnovelmyositisautoantibodiesinalargecohortofpatientswithinterstitiallungdisease
AT janssenbonasmontse prevalenceofnovelmyositisautoantibodiesinalargecohortofpatientswithinterstitiallungdisease
AT roodenburgbenschopclaudia prevalenceofnovelmyositisautoantibodiesinalargecohortofpatientswithinterstitiallungdisease
AT meekbob prevalenceofnovelmyositisautoantibodiesinalargecohortofpatientswithinterstitiallungdisease
AT vanmoorselcolinehm prevalenceofnovelmyositisautoantibodiesinalargecohortofpatientswithinterstitiallungdisease
AT gruttersjanc prevalenceofnovelmyositisautoantibodiesinalargecohortofpatientswithinterstitiallungdisease